Key result
Mn3O4 nanozymes combined with ADSC transplantation reduce infarct size and improve post-AMI cardiac function.
Why the study?
Does the combination of Mn3O4 nanozymes and adipose-derived stem cell transplantation improve therapeutic efficacy in a rat model of acute myocardial infarction?
Does the combination of Mn3O4 nanozymes and adipose-derived stem cell transplantation improve therapeutic efficacy in a rat model of acute myocardial infarction?
The combination of Mn3O4 nanozymes and adipose-derived stem cell transplantation synergistically improves therapeutic outcomes in a rat model of acute myocardial infarction by reducing oxidative stress and enhancing stem cell survival.
Background: Acute myocardial infarction (AMI) is a leading cause of mortality worldwide. Adipose-derived stem cell (ADSC) transplantation presents a promising therapeutic approach for AMI; however, the harsh microenvironment of the infarcted myocardium, characterized by hypoxia and oxidative stress, limits the survival and efficacy of ADSCs. Nanozymes (NZs), which have robust anti-oxidative enzyme-mimicking activities, have demonstrated potential in combating oxidative stress and improving cell viability. Methods: Mn3O4 NZs (Mn-Nzs), which have nanoflower-like structures were synthesized and their structure and multi-enzyme mimetic activities (superoxide dismutase, catalase, and glutathione peroxidase) were characterized. Blood biochemical parameters were measured in the heart, liver, spleen, lungs and kidneys of the rats, followed by hematoxylin and eosin (HE) staining. The impact of Mn3O4 NZs on reactive oxygen species (ROS) levels, and viability of ADSCs under oxidative stress was assessed in vitro. In vivo studies were conducted using a rat AMI model to evaluate the therapeutic efficacy of ADSC transplantation, in conjunction with Mn3O4 treatment. In addition, proteomic analysis was performed to elucidate the mechanisms of action underlying the therapeutic effects. Results: Mn 3 O 4 NZs exhibited multi-enzyme mimetic activities, including superoxide dismutase, catalase, and glutathione peroxidase, reducing reactive oxygen species levels and apoptosis in ADSCs under oxidative stress. In the AMI rat model, Mn-NZs had good biocompatibility and ADSC transplantation or Mn 3 O 4 NZs treatment alone significantly reduced infarct size, fibrosis levels, and improved microvascular density and heart function. Notably, the combination of Mn 3 O 4 NZs with ADSC transplantation enhanced ADSC survival and differentiation, amplifying therapeutic efficacy. Proteomic analysis revealed that Mn 3 O 4 4 NZs upregulated proteins associated with anti-oxidative damage, anti-inflammation, and anti-fibrosis pathways. In addition, Mn-NZs upregulated MMP8 via AKT pathway phosphorylation. Conclusion: The findings highlight a novel strategy integrating NZ anti-oxidant properties with stem cell transplantation to improve AMI treatment outcomes.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2025) studied Acute myocardial infarction. Mn3O4 nanozymes combined with adipose-derived stem cell transplantation vs. ADSC transplantation alone or Mn3O4 NZs alone was evaluated on Infarct size, fibrosis levels, microvascular density, and heart function. The combination of Mn3O4 nanozymes with adipose-derived stem cell transplantation enhanced ADSC survival and differentiation, reducing infarct size and improving heart function in an AMI rat model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: